Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-77474462 (Bermekimab) in Healthy Japanese Participants
NCT04544826Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bermekimab in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events, Number of Participants with Serious Adverse Events and 5 more. Started Oct 2020; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04544826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544826.